Cogent Biosciences, Inc. Increase (Decrease) in Accounts Receivable
Cogent Biosciences, Inc. (COGT) reported Increase (Decrease) in Accounts Receivable of -$2.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2022-03-15
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-09-30 was $0.00.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-06-30 was $0.00.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2020-03-31 was -$2.00M, a 637.63% decline year-over-year.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2020 was -$2.00M, a 702.41% decline from fiscal 2019.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2019 was $332.00K, a 60.38% decline from fiscal 2018.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2018 was $838.00K.
- Cogent Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2017 was -$98.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $0.00 derived: sum of 3 quarters · filed 2022-03-15 | -$2.00M 10-K · filed 2022-03-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | -$2.00M 10-Q · filed 2021-11-10 | -$880.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$2.00M 10-Q · filed 2021-08-16 | -$880.00K derived: sum of 3 quarters · filed 2021-08-16 | -$1.49M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$2.00M 10-Q · filed 2021-05-12 | -$880.00K derived: sum of 2 quarters · filed 2021-05-12 | -$1.49M derived: sum of 3 quarters · filed 2021-05-12 | -$2.04M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $508.00K derived: sum of 2 quarters · filed 2021-03-16 | -$40.00K derived: sum of 3 quarters · filed 2021-03-16 | $332.00K 10-K · filed 2021-03-16 |
| 2019-09-30 | -$612.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$1.16M derived: sum of 2 quarters · filed 2020-11-09 | -$788.00K 10-Q · filed 2020-11-09 | -$539.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$548.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$176.00K 10-Q · filed 2020-08-11 | $73.00K derived: sum of 3 quarters · filed 2020-08-11 | $290.00K derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $372.00K 10-Q · filed 2020-05-11 | $621.00K derived: sum of 2 quarters · filed 2020-05-11 | $838.00K derived: sum of 3 quarters · filed 2020-05-11 | $439.00K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $249.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $466.00K derived: sum of 2 quarters · filed 2020-03-26 | $67.00K derived: sum of 3 quarters · filed 2020-03-26 | $838.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$182.00K derived: sum of 2 quarters · filed 2019-11-12 | $589.00K 10-Q · filed 2019-11-12 | -$92.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | -$399.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $372.00K 10-Q · filed 2019-08-12 | -$309.00K derived: sum of 3 quarters · filed 2019-08-12 | -$56.00K derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $771.00K 10-Q · filed 2019-05-13 | $90.00K derived: sum of 2 quarters · filed 2019-05-13 | $343.00K derived: sum of 3 quarters · filed 2019-05-13 | $714.00K derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | -$681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$428.00K derived: sum of 2 quarters · filed 2019-03-28 | -$57.00K derived: sum of 3 quarters · filed 2019-03-28 | -$98.00K 10-K · filed 2019-03-28 |
| 2017-09-30 | $253.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $624.00K derived: sum of 2 quarters · filed 2018-11-13 | $583.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $371.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $330.00K 10-Q · filed 2018-08-13 | ||
| 2017-03-31 | -$41.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |